Literature DB >> 26338429

Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data.

William A Van Decker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26338429     DOI： 10.1007/s12350-015-0274-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  16 in total

1.  Subclinical Cardiotoxicity Associated With Cancer Therapy: Early Detection and Future Directions.

Authors:  Edward T H Yeh; Pimprapa Vejpongsa
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

2.  Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.

Authors:  Gregory T Armstrong; Vijaya M Joshi; Kirsten K Ness; Thomas H Marwick; Nan Zhang; DeoKumar Srivastava; Brian P Griffin; Richard A Grimm; James Thomas; Dermot Phelan; Patrick Collier; Kevin R Krull; Daniel A Mulrooney; Daniel M Green; Melissa M Hudson; Leslie L Robison; Juan Carlos Plana
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

3.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Authors:  G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

9.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.

Authors:  J Alexander; N Dainiak; H J Berger; L Goldman; D Johnstone; L Reduto; T Duffy; P Schwartz; A Gottschalk; B L Zaret
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

10.  Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.

Authors:  Jeffrey H Silber; Avital Cnaan; Bernard J Clark; Stephen M Paridon; Alvin J Chin; Jack Rychik; Alexa N Hogarty; Mitchell I Cohen; Gerald Barber; Monika Rutkowski; Thomas R Kimball; Cynthia Delaat; Laurel J Steinherz; Huaqing Zhao
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544
View more
  1 in total

1.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

Authors:  Rajiv Panwar; Prashant Bhattarai; Vishwesh Patil; Keyur Gada; Stan Majewski; Ban An Khaw
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.